• Users Online: 21
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2022  |  Volume : 2  |  Issue : 2  |  Page : 53-57

Psoriatic arthritis: Saudi retrospective observational study of manifestations and treatments


1 Medical Specialties Department, Rheumatology Section, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia
2 Regional Drug Information and Pharmacovigilance Center, Tabuk Health Affairs, Ministry of Health, Tabuk, Kingdom of Saudi Arabia

Correspondence Address:
Dr. Ibrahim Abdulrazag Al-Homood
Medical Specialties Department, Rheumatology Section, King Fahad Medical City, P.O. Box 59046, Riyadh 11525
Kingdom of Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ara.ara_14_22

Rights and Permissions

Objectives: Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease associated with psoriasis. In this study, we aimed to assess clinical features and the response rates to various biological agents among patients with PsA in the Kingdom of Saudi Arabia. Materials and Methods: A retrospective study where 39 patients diagnosed with PsA based on ClASsification criteria for PsA criteria for the period 2015–2019, were recruited from rheumatology outpatient clinics at KFMC, Riyadh, Saudi Arabia. Results: Thirty-nine PsA patients (31 females [79.5%] and eight males [20.5%]) were reviewed. The median age at disease onset was 36 years (ranging from 20 to 61 years). The median disease duration was 3 years. Peripheral arthritis reported in 92% and axial involvement in 28.2% of our patients. Fifteen percent of our patients developed enthesitis, whereas 12.5% had dactylitis. The mean duration for adalimumab (ADA) as a first-line treatment was 104 weeks, whereas etanercept (ETA) was 120 weeks. However, ADA had the longest duration in the second-line therapy (177 weeks), and secukinumab (SEC) had the longest duration (209 weeks) in the third-line therapy. ADA was discontinued in 76.9% of our patients due to inefficacy, whereas the most adverse events were reported with SEC and ETA (7.1%). Conclusion: Our study provided insights on the demographics, characteristics, and responses to various biological treatments of PsA patients in Saudi Arabia.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed40    
    Printed4    
    Emailed0    
    PDF Downloaded8    
    Comments [Add]    

Recommend this journal